REVIEWER: Dr. Mark S. Freedman, Director, Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Canada

Redefining therapeutic efficacy
Conclusions

New data on novel and emerging therapies were the centrepiece of the 2014 joint meeting of the Americas and European Committee for Research and Treatment of Multiple Sclerosis (ACTRIMS/ECTRIMS), with results suggesting that clinical standards are being redefined for optimal disease control in relapsing-remitting multiple sclerosis (RRMS).